EW - Edwards Lifesciences Corporation
191.96 0.00 (0.00%)
After hours: 4:54PM EDT
| Previous Close | 191.76 |
| Open | 191.61 |
| Bid | 192.00 x 2200 |
| Ask | 192.54 x 800 |
| Day's Range | 191.50 - 193.73 |
| 52 Week Range | 134.53 - 197.86 |
| Volume | 1,035,193 |
| Avg. Volume | 1,217,990 |
| Market Cap | 40.024B |
| Beta (3Y Monthly) | 0.96 |
| PE Ratio (TTM) | 53.35 |
| EPS (TTM) | 3.60 |
| Earnings Date | Jul 24, 2019 - Jul 29, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 193.11 |
- Zacks•7 hours ago
CMS' Final Verdict on TAVR: A Boon or Bane for MedTech?
While the industry bigwigs are keen to welcome the new CMS ruling, companies like Heart Valve Voice US are not lagging to pen their resistance against a revised policy.
- Moody's•yesterday
Edwards Lifesciences Corporation -- Moody's announces completion of a periodic review of ratings of Edwards Lifesciences Corporation
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Edwards Lifesciences Corporation and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.
- PR Newswire•4 days ago
Edwards Comments On Updated TAVR National Coverage Determination
"We commend CMS on its thoughtful approach toward updating the TAVR policy. Throughout the NCD process, Edwards emphasized that the priority must be ensuring timely patient access to high-quality care, so that clinicians can provide all people with heart valve disease with the therapy that is right for them.
- Investor's Business Daily•11 days ago
Why This Method Of Replacing A Faulty Heart Valve Is Gaining Steam
A nonsurgical method of heart-valve replacement, dubbed TAVR, is gaining steam in the U.S. — propping up medical technology companies Edwards and Medtronic, an analyst said Friday.
- Simply Wall St.•12 days ago
Read This Before Buying Edwards Lifesciences Corporation (NYSE:EW) Shares
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
- Zacks•12 days ago
HOLX or EW: Which Is the Better Value Stock Right Now?
HOLX vs. EW: Which Stock Is the Better Value Option?
- Markit•14 days ago
See what the IHS Markit Score report has to say about Edwards Lifesciences Corp.
Edwards Lifesciences Corp NYSE:EWView full report here! Summary * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for EW with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting EW. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold EW had net inflows of $1.66 billion over the last one-month. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•18 days ago
DexCom and Companion Medical Collaboration to Support CGM
The collaboration enables InPen users to display real-time insulin data in Dexcom's (DXCM) CLARITY Diabetes Management Software.
- PR Newswire•21 days ago
Edwards Lifesciences To Present At The Goldman Sachs 40th Annual Global Healthcare Conference
IRVINE, Calif. , June 4, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, is ...
- Benzinga•21 days ago
The Daily Biotech Pulse: ASCO Presentations From Roche, Celgene & More, Edwards Recommends Rejection Of Mini-Tender Offer
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 3) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Array Biopharma ...
- PR Newswire•22 days ago
Edwards Lifesciences Recommends Stockholders Reject "Mini-Tender Offer" By TRC Capital Corporation
IRVINE, Calif., June 3, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has received notice of an unsolicited "mini-tender offer" by TRC Capital Corporation to purchase up to 1,000,000 shares, or approximately 0.48 percent of the company's outstanding shares of common stock as of the date of the offer. Edwards does not endorse this unsolicited offer and recommends that the company's stockholders reject the offer, either by doing nothing in response or by withdrawing their shares from the offer, if they have responded. Edwards is not affiliated or associated in any way with TRC Capital, its mini-tender offer or the offer documentation.
- Simply Wall St.•27 days ago
Why We Like Edwards Lifesciences Corporation’s (NYSE:EW) 23% Return On Capital Employed
Today we'll evaluate Edwards Lifesciences Corporation (NYSE:EW) to determine whether it could have potential as an...
- Zacks•last month
Why Is Edwards Lifesciences (EW) Down 2.9% Since Last Earnings Report?
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- PR Newswire•last month
Edwards Announces Milestones For Transcatheter Mitral Program
Today at the EuroPCR annual course in Paris, new 6-month data from the CLASP study of the PASCAL system were presented by Konstantinos Spargias, M.D., from the Hygeia Hospital in Athens, Greece. Patients enrolled in the CLASP study had clinically significant mitral regurgitation (MR) despite optimal medical therapy. The results from treatment with the PASCAL system demonstrated sustained positive outcomes at six months, including 81 percent of patients with mild (1+) or none/trace MR and 98 percent with 2+ MR, with echo core lab adjudication. Patients experienced clinically and statistically significant improvements in functional status, exercise capability and quality of life sustained at six months.
- Zacks•last month
HOLX vs. EW: Which Stock Is the Better Value Option?
HOLX vs. EW: Which Stock Is the Better Value Option?
- Investopedia•last month
Top 5 Health Care Stocks of 2018 by Performance
The healthcare sector performed well in 2018, driven by positive growth in sub-segments such as medical devices, health insurance, hospitals, nursing homes, and pharmaceuticals, which offset losses in biomedical and genetics, home healthcare, medical, and dental supplies. Moving ahead into 2019, as the decade-long expansion faces a period of heightened volatility and risk, the health care sector should benefit from a shift towards more defensive sectors. In a recent sector roundup from Charles Schwab, the firm rated health care at "outperform," citing the group’s strong balance sheets, attractive dividend yields, and improved cost structure.
- PR Newswire•last month
Edwards Lifesciences' Every Heartbeat Matters Charitable Initiative On Track to Impact 1.5 Million Underserved People By 2020
IRVINE, Calif., May 15, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the Every Heartbeat Matters signature charitable initiative is on schedule to meet its goal of impacting the global burden of heart valve disease. The initiative, which involves the education, screening and treatment of 1.5 million underserved people by 2020, is supported by grants from Edwards Lifesciences Foundation, donations of Edwards heart valve technologies, volunteer support and the dedicated work of 60 non-profit partners. "Since the Every Heartbeat Matters initiative began five years ago, we have made substantial progress in building a global community that is addressing the burden of heart valve disease for underserved people," said Amanda Fowler, executive director, Edwards Lifesciences Foundation.
- GuruFocus.com•last month
Edwards Lifesciences Corp (EW) Chairman & CEO Michael A Mussallem Sold $5.9 million of Shares
Chairman & CEO of Edwards Lifesciences Corp (NYSE:EW) Michael A Mussallem sold 32,800 shares of EW on 05/10/2019 at an average price of $178.99 a share.
- Simply Wall St.•2 months ago
Investors Who Bought Edwards Lifesciences (NYSE:EW) Shares Five Years Ago Are Now Up 314%
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
- PR Newswire•2 months ago
Favorable Study Outcomes Presented On Edwards Aortic Valves With RESILIA Tissue
TORONTO, May 7, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced results from the COMMENCE clinical study. The data show that Edwards' bioprosthetic surgical aortic valves featuring the company's novel RESILIA tissue platform continued to demonstrate favorable safety and hemodynamic performance through a median of four years follow-up, with no events of structural valve deterioration (SVD). The COMMENCE study enrolled 694 patients, 144 (21 percent) of which were under the age of 60 when they had surgical valve replacement.
- Zacks•2 months ago
Masimo Gets CE Mark for ANI Module, Enhances Root Platform
Masimo (MASI) obtains CE mark of the ANI module for the Masimo Root Patient Monitoring and Connectivity Hub, which is likely to strengthen its expanding Root platform.
- PR Newswire•2 months ago
Edwards Lifesciences To Webcast Annual Meeting Of Stockholders
IRVINE, Calif. , May 1, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, will ...
- GuruFocus.com•2 months ago
Edwards Lifesciences Corp (EW) Chairman & CEO Michael A Mussallem Sold $5.7 million of Shares
Chairman & CEO of Edwards Lifesciences Corp (NYSE:EW) Michael A Mussallem sold 32,800 shares of EW on 04/29/2019 at an average price of $174.73 a share.
